MediWound Germany GmbH

MediWound Germany GmbH
Dr. Ulrich Striebl
Hans-Sachs-Straße 100
65428 Rüsselsheim

Telefon: +49 173 298 3947
Internet: www.mediwound.com
E-Mail: ulrich.striebl@mediwound.com

Committed to Innovation
Dedicated to Improving Patients' Lives

MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, biotherapeutic solutions for tissue repair and regeneration.

Our strategy leverages our enzymatic technology platform, focused on next-generation bio active therapies for burn, wound care and tissue repair.

NexoBrid®, our commercial orphan biological product for eschar removal of severe thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours and does not harm surrounding viable tissue.

Nexobrid is currently marketed in the European Union as well as in other International markets and is at registration stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

For more information visit our homepage: www.mediwound.com